Problem Solving in Cancer Immunotherapy

1) Immunotherapy - past, present and future; 2) Beyond exhausted. Tumour immune checkpoints and their therapeutic targets; 3) Checkpoint inhibitors: where have we come from and where are we going?; 4) Immune-related toxicity of checkpoint inhibitors; 5) Predicting response to immunotherapy; 6) Difficulties in assessment of PD-L1 expression; 7) Radiological assessment of immunotherapy; 8) Combination immunotherapies - multimodality treatment; 9) The future of novel vaccine strategies in cancer immunotherapy; 10) Genetically modified cell therapy for solid tumours; 11) Adoptive cell therapy for haematological malignancies; 12) Tumour infiltrating lymphocytes (TILs).
Case Studies: 1) A case of cytokine release syndrome; 2) High Dose Interleukin- 2 Induced Myocarditis; 3) Multiorgan toxicity following combination immunotherapy in melanoma; 4) Immune-related Endocrine Toxicity Following Immune Checkpoint Inhibitor Therapy; 5) Checkpoint Inhibitors in patients with autoimmune disease; 6) A patient with Lung Cancer who received an immune checkpoint inhibitor in the first-line setting; 7) A Case of Sinonasal Mucosal Melanoma; 8) Adjuvant immunotherapy in metastatic melanoma; 9) Ongoing response after stopping immunotherapy; 10) A case of pneumonitis following treatment with an anti-PD1 antibody in a patient with NSCLC; 11) A case of colitis following combination immunotherapy within a clinical study for Small Cell Lung cancer; 12) Jaundice after pembrolizumab in a patient with melanoma and brain metastases; 13) Localised scleroderma as a manifestation of a skin immune-related adverse event in a patient with metastatic melanoma treated with pembrolizumab; 14) Intracranial melanoma response to Combination Ipilimumab and Nivolumab; 15) A case of delayed response to immunotherapy in a patient with acral melanoma; 16) A Case of Facial Nerve Palsy in a Patient with Renal Cell Carcinoma Treated with Nivolumab; 17) A Case of Acute Kidney Injury in a Patient on Combination Immunotherapy for Metastatic Melanoma; 18) Merkels cell cancer receiving immunotherapy; 19) A Case of Immune Pneumonitis Following Immunotherapy for Metastatic Melanoma; 20) Patient with ureteric TCC on anti-PD1 antibody - complicated by sarcoidosis; 21) A case of renal cell carcinoma treated with ipilimumab and nivolumab; 22) A case of ocular toxicity from Nivolumab; 23) A case of multiple immune related toxicities in a patient with breast cancer on a checkpoint inhibitor and chemotherapy; 24) Oncolytic viral therapy: T-VEC